News

Novo Nordisk CEO steps down as Wegovy maker faces increased competition
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...
Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...
Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down
Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...
Dagens PS on MSN2d
Vd:n på Novo Nordisk får gå efter kursfall
Viktnedgångsföretaget Novo Nordisk vd Lars Fruergaard Jørgensen kommer att avgå. Detta efter ett kraftigt börsfall för aktien ...
STAT5d
Novo Nordisk strikes deal with Septerna to develop obesity pills
You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...
Reuters3d
Novo Nordisk A/S
Future of Healthcategory· 2:31 PM UTC Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments Novo Nordisk has struck a collaboration and licensing deal with U.S ...
Wall Street Journal4d
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...